The BRAF kinase is mutated, typically Val 600RGlu (V600E), to induce an active oncogenic state in a large fraction of melanomas, thyroid cancers, hairy cell leukaemias and, to a smaller extent, a wide spectrum of other cancers 1,2 . BRAF V600E phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylate and activate the ERK1 and ERK2 kinases, stimulating the mitogen-activated protein kinase (MAPK) pathway to promote cancer 3 . Targeting MEK1/2 is proving to be an important therapeutic strategy, given that a MEK1/2 inhibitor provides a survival advantage in metastatic melanoma 4 , an effect that is increased when administered together with a BRAF V600E inhibitor 5 . We previously found that copper (Cu) influx enhances MEK1 phosphorylation of ERK1/2 through a Cu-MEK1 interaction 6 .
The BRAF kinase is mutated, typically Val 600RGlu (V600E), to induce an active oncogenic state in a large fraction of melanomas, thyroid cancers, hairy cell leukaemias and, to a smaller extent, a wide spectrum of other cancers 1, 2 . BRAF V600E phosphorylates and activates the MEK1 and MEK2 kinases, which in turn phosphorylate and activate the ERK1 and ERK2 kinases, stimulating the mitogen-activated protein kinase (MAPK) pathway to promote cancer 3 . Targeting MEK1/2 is proving to be an important therapeutic strategy, given that a MEK1/2 inhibitor provides a survival advantage in metastatic melanoma 4 , an effect that is increased when administered together with a BRAF V600E inhibitor 5 . We previously found that copper (Cu) influx enhances MEK1 phosphorylation of ERK1/2 through a Cu-MEK1 interaction 6 .
Here we show decreasing the levels of CTR1 (Cu transporter 1), or mutations in MEK1 that disrupt Cu binding, decreased BRAF V600Edriven signalling and tumorigenesis in mice and human cell settings. Conversely, a MEK1-MEK5 chimaera that phosphorylated ERK1/2 independently of Cu or an active ERK2 restored the tumour growth of murine cells lacking Ctr1. Cu chelators used in the treatment of Wilson disease 7 decreased tumour growth of human or murine cells transformed by BRAF V600E or engineered to be resistant to BRAF inhibition. Taken together, these results suggest that Cu-chelation therapy could be repurposed to treat cancers containing the BRAF V600E mutation.
Decreasing Ctr1 expression suppresses MAPK phenotypes in Drosophila and signalling in mammalian cells. In a cupric setting MEK1 also binds Cu, and Cu chelation decreases MEK1/2 kinase activity 6 . Cu and, to a smaller extent, silver-which is isoelectric to cuprous Cu-increased the phosphorylation of ERK2 by MEK1, whereas other tested metals had no effect (Extended Data Fig. 1a ). Given these results and the dependence of BRAF mutation-positive cancers on MEK1/2 for tumor growth 8 , we investigated whether decreasing the influx of Cu affects BRAF V600E oncogenesis. BRAF V600E was expressed in Ctr1 1/1 and Ctr1 2/2 mouse embryonic fibroblasts (MEFs) 9 , and intracellular Cu deficiency of the latter was confirmed by increased copper chaperone for superoxide dismutase (CCS) levels 10 (Fig. 1a, b) . The BRAF V600E -transformed Ctr1 2/2 MEFs showed decreased phosphorylated ERK1/2 (P-ERK1/2), cell growth, and tumour kinetics, effects that were rescued by expressing CTR1 but not the transport-defective mutant 11 CTR1 M154A (Fig. 1a-d and Extended Data Figs 2a-c and 10a, b). Thus, the Cu-transport function of CTR1 is required for robust BRAF V600E signalling and tumorigenesis.
To assess whether decreasing the binding of Cu to MEK1 affects BRAF V600E -driven tumorigenesis, targeted mutagenesis was undertaken, which revealed that M187A, H188A, M230A, H239A and one other mutation decreased the ability of MEK1 to bind a Cu-charged resin and phosphorylate ERK1/2 (Extended Data Fig. 3a-c) . A metal-catalysed oxidation reaction followed by mass spectrometry identified oxidation at H188, M230A, H239 and two other sites ( Fig. 1e and Extended Data Fig. 4 ), suggesting that these residues reside within 10 Å of a Cu atom 12 .
We thus focused on H188, M230 and H239 and included M187 as well, even though the oxidation status of this site could not be determined, it lies adjacent to H188 and was similarly required for Cu binding and kinase activity ( Fig. 1e and Extended Data Figs 3c and 4e). These four residues are conserved in MEK2 (Extended Data Fig. 5 ), which, like MEK1, also bound a Cu-charged resin and was inhibited by tetrathiomolybdate (TTM), a Cu chelator (Extended Data Fig. 1b, c) . In the three-dimensional MEK1 structure 13 , these four amino acids also clustered such that each was no more than 12.5 Å from the next (Fig. 1e ). Combined mutations at these sites progressively decreased MEK1 kinase activity and affinity for a Cu-charged resin, with mutations at all four sites (copper-binding mutant; CBM) having the largest defect in kinase activity, even in the presence of a constitutively active mutation (S218D/ S222D; DD) 14 or excess Cu ( Fig. 1f-j) . Nevertheless, MEK1 CBM was still phosphorylated in BRAF V600E -transformed cells, underwent cooperative unfolding and possessed similar thermostability to that of MEK1, as assessed by both circular dichroism and differential scanning fluorimetry ( Fig. 1k , l and Extended Data Figs 6a-d and 10c). To exclude the possibility that the CBM mutation decreased kinase activity independently of Cu binding, we took advantage of the fact that MEK5 is highly similar to MEK1/2, yet lacks two sites that are important for binding Cu (Extended Data Fig. 5 ) and did not bind the Cu-charged resin or show changes in kinase activity in the presence of Cu or TTM ( Fig. 1m, n) . Specifically, introducing a CBM-equivalent (CBM-E) mutation into MEK5 was found to have no overt effect on the ability of MEK5 to phosphorylate substrates myelin basic protein (MBP) or ERK5 in vitro or in cells ( Fig. 1o , p). Given these results, we tested and found that the decrease in P-ERK1/2 and tumour growth of BRAF V600E -transformed Ctr1 1/1 MEFs due to knockdown of endogenous Mek1 messenger RNA by short hairpin RNA (shRNA) ( Fig. 1k ) was rescued by expressing wild-type but not CBM mutant MEK1 resistant to shRNA-mediated knockdown (Fig. 1l , q and Extended Data Fig. 10c ). Thus, under normal Cu homeostasis, inhibiting Cu binding in MEK1 retards BRAF V600Edriven signalling and tumorigenesis.
We next tested whether bypassing the requirement of MEK1/2 for Cu restores BRAF V600E -driven signalling and tumorigenesis to Ctr1 2/2 MEFs. MEK1 was engineered to be independent of Cu by fusing the ERK1/2-binding region of MEK1 protein 15 to the kinase domain of MEK5 protein, rendered active (S311D/T315D; DD) 16 because MEK5 is a substrate of MEKK2 and MEKK3 (ref. 17) . Expressing MEK1-MEK5 DD resulted in high levels of P-ERK1/2 in Ctr1 2/2 MEFs (Fig. 1r, s ), in contrast to similarly activated MEK1 DD , which remained sensitive to TTM ( Fig. 1j ). Furthermore, MEK1-MEK5 DD restored tumour growth to these Ctr1 2/2 MEFs ( Fig. 1t and Extended Data Fig. 10d ). Similarly, expressing ERK2 R67S , which increases ERK2 autophosphorylation in a MEK1/ 2-independent fashion 18 , ERK2 D321N , which renders the kinase insensitive to phosphatases 19 , or ERK2 GOF , which combines these two mutations, also led to robust ERK1/2 phosphorylation and restored tumour 
Mek1
Ect Results were compared using a one-tailed unpaired t-test (c, t) or a one-way ANOVA followed by a Tukey's multi-comparison post test (d, q, w). Two asterisks, P , 0.01; four asterisks, P , 0.0001. e, MEK1 structure (PDB 3EQD) denoting amino acids M187, H188, M230 and H239 and the intervening space (Å ) 13 . f-j, m-o, Immunoblot detection of the indicated recombinant proteins bound to a resin charged with or without Cu (f, m) or phosphorylated (P) or total (T) recombinant proteins with or without 50 mM TTM, a seven-step increase in TTM from 0 to 50 mM, or either 2.5 molar equivalents or 2.5 mM CuSO 4 (g, h, i, j, n, o). Gel images are representative of at least two technical replicates.
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growth to the Ctr1 2/2 MEFs (Fig. 1u -w and Extended Data Fig. 10d ). Thus, while decreasing Cu levels will certainly have pleiotropic effects 20 that could affect the MAPK pathway 21 , activating this pathway in a manner independent of Cu nevertheless restores signalling and tumorigenesis in cells deficient in Cu influx.
To investigate the relationship between Cu and endogenous oncogenic BRAF in tumorigenesis, CTR1 was stably knocked down by shRNA in BRAF mutation-positive and mutation-negative melanoma cell lines. Knockdown of CTR1 decreased P-ERK1/2 levels in all tested cell lines, although only the BRAF mutation-positive cell lines showed decreased tumour growth ( Fig. 2a -c and Extended Data Fig. 10b ), consistent with a dependence of BRAF V600E tumorigenicity on the MEK1/2 proteins 8 . Knockdown of CTR1 also inhibited the tumour growth of one of two tested NRAS mutation-positive melanoma cell lines (Extended Data Fig. 7a, b ). Finally, loss of Ctr1 had no effect on the ability of a different oncogene, CMYC T58A , to promote tumour growth ( Fig. 2d, e ). These results suggest a specific requirement for Cu in cancers that are particularly dependent on the MAPK pathway.
We next evaluated the requirement for Cu influx in vivo during spontaneous cancer development. Mice harbouring floxed conditional null or wild-type Ctr1 alleles 22 were crossed into a background having one Cre-activated (CA) conditional oncogenic allele of Braf and two floxed conditional null alleles of Trp53 (Braf CA/1 ;Trp53 flox/flox , BP) 23 , which on intranasal administration of adenovirus expressing Cre recombinase (AdCre) converts Braf CA to an oncogenic Braf V600E allele and Trp53 flox/flox to null alleles, leading to the development of lung adenocarcinomas 23 . AdCre was administered to cohorts of Ctr1 1/1 and Ctr1 flox/flox BP mice to induce cancer development and, in the latter case, to convert Ctr1 flox/flox to null alleles. Tumours arising in both cohorts showed the appropriate recombination of the Braf CA , Trp53 flox and 
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Ctr1 flox alleles, and targeted loss of Ctr1 did not result in a weight loss (Extended Data Fig. 8a, b ). Ctr1 flox/flox BP mice showed a decrease in the number of visible surface lesions, the area of abnormal lung tissue, and P-ERK1/2 staining in tumours and also a 15% survival advantage over Ctr1 1/1 BP mice ( Fig. 3a-g and Extended Data Fig. 10a, b) . Thus, the loss of Ctr1 retards BRAF V600E -driven tumorigenesis, leading to a survival advantage.
The Cu chelators D-penicillamine, trientine and TTM are efficacious, long-term treatments for lowering systemic Cu levels in individuals with the Cu-overload disorder Wilson disease 7 . Capitalizing on these drugs, we found that TTM decreased the growth of BRAF V600E , but not ERK2 GOF , MEK1-MEK5 DD or CMYC T58A -transformed MEFs in soft agar. The growth of BRAF mutation-positive melanoma cell lines in soft agar was also inhibited by TTM to various degrees in a dosedependent manner, whereas BRAF/NRAS mutation-negative lines were resistant to TTM ( Fig. 4a and Extended Data Fig. 10e ). Oral TTM treatments for only two weeks also decreased the size of tumours in mice injected with either BRAF V600E -transformed MEFs or the BRAF mutationpositive melanoma cell line DM440, with no negative effect on mouse weight (Fig. 4b, c and Extended Data Figs 9 and 10e). This effect could be ascribed to a decrease in MEK1/2 kinase activity, because TTM halved the number of P-ERK1/2-positive cells in BRAF V600E -driven tumours and failed to inhibit tumour growth of ERK2 GOF -transformed cells ( Fig. 4d, e ). To investigate more aggressive Cu-lowering therapeutic methods, mice injected with BRAF V600E -transformed MEFs were provided with a Cu-deficient (CuD) diet supplemented with Cu and orally treated with vehicle alone for two weeks, or provided with a CuD diet and treated for two weeks with vehicle alone, oral TTM, or oral TTM followed by oral trientine (Fig. 4f ). Tumours in mice fed with a CuD diet trended towards being smaller, although this did not reach significance (P 5 0.055). Combining this diet with TTM blocked the development of visible tumours during the two weeks of treatment, although tumours quickly emerged after treatment ceased. However, mice treated with oral trientine after TTM showed a more durable response ( Results were compared using a one-tailed unpaired t-test (b, c, d) or a one-way ANOVA followed by a Tukey's multi-comparison post test (a, g, l). Two asterisks, P , 0.01; three asterisks, P , 0.001. Gel images are representative of at least two technical replicates.
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and Extended Data Fig. 10e ). Thus, Cu-lowering strategies used to manage Wilson disease 7 could be repurposed for the treatment of BRAF V600Edriven cancers.
BRAF V600E inhibitors such as vemurafenib have a limited duration of response as a result of acquired resistance that is often associated with the reactivation of MEK1/2 kinases 24 . One reported mechanism of resistance is the acquisition of an activating C121S mutation 25 in MEK1. Although MEK1 C121S had elevated kinase activity in vitro, it still bound to the Cu-charged resin and its kinase activity was still inhibited by TTM (Fig. 4h, i) . Moreover, although expressing MEK1 C121S in the BRAF mutation-positive melanoma cell line A375 increased P-ERK1/2 levels and imparted resistance to vemurafenib, in contrast with the same cells expressing MEK1, the MEK1 C121S -expressing A375 cells nevertheless remained sensitive to TTM in vivo (Fig. 4j-l and Extended Data Fig. 10f ). Thus, Cu chelation decreases tumorigenicity driven by a mutation that confers resistance to a BRAF V600E inhibitor.
Although the detailed mechanism underlying the requirement of Cu for robust MEK1/2 kinase activity remains to be explained, we have shown that decreasing the influx, bioavailability and binding of Cu to MEK1 decreases MEK1(2) kinase activity and oncogenic BRAF-driven tumorigenesis. Cu chelators, which are generally safe and economical drugs that have been given daily for decades to manage Cu levels in patients with Wilson disease 7 , also decreased oncogenic BRAF-and MEK1-driven tumorigenesis. Thus, inhibiting MEK1/2 kinase activity with Cu chelators, perhaps in combination with other MAPK pathway inhibitors, may merit clinical consideration for the treatment of not only BRAF mutation-positive cancers but also cancers developing resistance to BRAF V600E and potentially even MEK1/2 inhibitors.
METHODS SUMMARY
Binding to Cu-charged resin, in vitro kinase assays, metal-catalysed oxidation, circular dichroism and differential scanning fluorimetry were performed as described previously 6, [26] [27] [28] . Standard methods were used to generate cell lines and assay RNA and protein levels and growth in soft agar. Measurements of tumour growth in immunocompromised mice treated with the indicated drugs and fed with the indicated diets as well as monitoring the tumour development and lifespan of BP mice 23 in a Ctr1 1/1 or a Ctr1 flox/flox background 22 treated intranasally with AdCre 23 were performed under a protocol approved by the Institutional Animal Care and Use Committee.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Cell lines. Ctr1 1/1 and Ctr1 2/2 MEFs (immortalized with a plasmid encoding the SV40 T-Ag gene) were described previously 9 . A375 was purchased from ATCC. DM175, DM440, DM443, DM598, DM646, DM738 and DM792 cell lines were provided by D. S. Tyler 29 . Mouse lung cancer cell lines were created and cultured as described previously 30 . Ctr1 1/1 and Ctr1 2/2 immortalized MEFs and A375, DM175, DM646, DM440, DM598, DM738 and DM792 cells lines were stably infected with retroviruses derived from pBABE, pWZL or pSUPER-based vectors (see plasmids below) as described previously 31 . Ctr1 1/1 MEFs were stably transfected with pCMVbased vectors (see plasmids below), using established protocols. Plasmids. pBABEpuro-MYC-HIS-BRAF V600E , pSUPER-retro-puro-tetO-RALBscramble (encoding RALB scramble shRNA), pBABEpuro-CMYC T58A and pCMV-HA-MEK1 WT were described previously 6, [32] [33] [34] . pBABEbleo-Flag-BRAF V600E was created by PCR subcloning BRAF V600E from the pBABEpuro-MYC-HIS-BRAF V600E plasmid with primers designed to include an amino-terminal Flag tag. pWZLblasti-CTR1 WT and pWZLblasti-CTR1 M154A were created by PCR subcloning CTR1 WT or CTR1 M154A from the pCDNA3.1-CTR1 WT or pCDNA3.1-CTR1 M154A plasmids 11 . pGEX6P1-GST-HA-MEK1 WT (GST, glutathione S-transferase) and pWZLblasti-HA-MEK1 WT were created by PCR subcloning MEK1 WT from the pENTR1-MEK1 WT plasmid 35 with primers designed to include an N-terminal haemagglutinin tag. pGEX6P1-GST-HA-MEK1 CBM and pWZLblasti-HA-MEK1 CBM (M187A/H188A/ M230A/H239A; CBM), pGEX6P1-GST-HA-MEK1 C121S , pWZLblasti-HA-MEK1 C121S , pGEX6P1-GST-HA-MEK1 M187A/H188A and pGEX6P1-GST-HA-MEK1 M230A/H239A were created by introducing mutations corresponding to the indicated amino-acid changes by site-directed mutagenesis into MEK1 WT from the pENTR1-MEK1 WT plasmid 35 followed by PCR subcloning with primers designed to include an Nterminal HA tag. pGEX6P1-GST-HA-MEK5 WT and pWZLblasti-HA-MEK5 WT were created by PCR subcloning MEK5 WT from the pWZLneo-Myr-Flag-MEK5 plasmid 32 . pGEX6P1-GST-HA-MEK5 CBM-E and pWZLblasti-HA-MEK5 CBM-E (L280A/H281A/M323A/Q332A; CBM-E) were created by introducing mutations corresponding to the indicated amino-acid changes by site-directed mutagenesis into MEK5 WT from the pWZLneo-Myr-Flag-MEK5 plasmid 32 followed by PCR subcloning with primers designed to include an N-terminal HA tag. pGEX6P1-GST-HA-ERK5 K84R was created by introducing a mutation corresponding to the indicated amino-acid change by site-directed mutagenesis into ERK5 WT from the pWZLneo-Myr-Flag-ERK5 plasmid 32 followed by PCR subcloning with primers designed to include an N-terminal HA tag. pWZLblasti-HA-ERK5 WT was created by PCR subcloning ERK5 WT from the pWZLneo-Myr-Flag-ERK5 plasmid 32 with primers designed to include an N-terminal HA tag. pBABEpuro-HA-MEK1-MEK5 DD and pWZLblast-HA-MEK1-MEK5 DD (S311D/T315D; DD) were created by introducing mutations corresponding to the indicated amino-acid changes by site-directed mutagenesis into MEK5 WT from the pWZLneo-Myr-Flag-MEK5 plasmid 32 followed by two-step PCR to fuse MEK1 (nucleotides 1-201) to MEK5 (nucleotides 498-1344) in frame with primers to include an N-terminal HA-tag. pGEX6P1-GST-HA-ERK2 K54R , pWZLblasti-HA-ERK2 R67S , pWZLblasti-HA-ERK2 D321N , pBABEpuro-HA-ERK2 GOF and pWZLblasti-HA-ERK2 GOF (R67S/D321N; GOF) were created by introducing mutations corresponding to the indicated amino acid changes by site-directed mutagenesis into ERK2 WT from the pDONR223-ERK2 WT plasmid 36 followed by PCR subcloning with primers designed to include an Nterminal HA tag. pSUPER-retro-puro-tetO-CTR1-shRNA was created to express the human CTR1 shRNA target sequence 59-AAAGCCCAGCTTTCTCTTTGG-39. pSUPER-retro-puro-tetO-Mek1-shRNA was created to express the mouse Mek1 shRNA target sequence 59-GCCTCTCAGCTCATATGGAAT- 39 (ref. 37) . pCMV-HA-MEK1 encoding mutants M94A, H100A, H119A, M187A, H188A, C207A, M230A, H239A, M256A, M308A, C341A and H358A were created by site-directed mutagenesis of MEK1 WT from the pCMV-HA-MEK1 WT plasmid. Reverse transcriptase PCR. RNA was purified from MEFs or tumour cell lines and reverse transcribed (RT) as described previously 30 , and then PCR amplified with the primers 59-ATCCTCATCAGCTCCCAATG-39 and 59-CACATCACCA TGCCACTTTC-39 to detect human BRAF; 59-CTGTTTTCCGGTTTGGTGAT-39 and 59-TGCCCAACAGTTTTGTGTGT-39 to detect human CTR1; 59-ATGAAC CATATGGGGATGAACCATA-39 and 59-TCAATGGCAGTGCTCTGTGATG TC-39 to detect mouse Ctr1; 59-GCACAGTCAAGGCCGAGAAT-39 and 59-GC CTTCTCCATGGTG GTGAA-39 to detect mouse Gapdh; 59-CCTTGAGGCCT TTCTTACCC-39 and 59-CCCACGATGTACGGAGAGTT-39 to detect human MEK1; 59-GTGAACTCACGTGGGGAGAT-39 and 59-CAGGAGGAGGAATG GGGTAT-39 to detect mouse Mek1; 59-CCTTGCAGAAGAAGCTGGAG-39 and 59-TCGGGACATGATATGCTTTG-39 to detect human MEK1-MEK5 DD ; 59-TG ATCACACAGGGTTCCTGA-39 and 59-TGGAAAGATGGGCCTGTTAG-39 to detect human ERK2; 59-GAGAGACCCTCACTGCTG-39 and 59-GATGGTACA TGACAAGGTGC-39 to detect human GAPDH; and 59-ACGAGCACAAGCTCA CC-39 and 59-TTTCCACACCTGGTTGC-39 to detect human CMYC. The fold change in the ratio of CTR1 mRNA to total GAPDH mRNA was measured in ImageJ software by boxing each band per representative image with the rectangular selection tool, and calculating the total area of the band in pixels. The total area of the CTR1 mRNA band in pixels was normalized to the total area of the total GAPDH mRNA band in pixels. The fold change is shown in figures. Immunoblot analysis. Equal quantities of lysates were isolated from the indicated cell lines after 24 h of serum starvation and then resolved by SDS-PAGE and immunoblotted as described previously 6 with one of the following primary antibodies: mouse anti-MEK1, rabbit anti-ERK2, rabbit anti-MEK2, mouse anti-MEK1/2, rabbit anti-ERK1/2, rabbit anti-ERK5, rabbit anti-phospho(Ser 217/221)-MEK1/2, rabbit anti-phospho(Thr 202/Tyr 204)-ERK1/2, rabbit anti-phospho(Thr 218/Tyr 220)-ERK5 (Cell Signaling Technology), mouse anti-HA (Covance), rabbit anti-CCS (Santa Cruz Biotechnology), mouse anti-b-actin (Sigma), mouse anti-MEK5 (BD Transductions Laboratories), rat anti-myelin basic protein (Millipore) or mouse anti-phospho(Thr 98)-MBP (Millipore), followed by detection with one of the following horseradish peroxidase-conjugated secondary antibodies: goat anti-rabbit IgG, goat anti-mouse IgG (Invitrogen), goat anti-mouse light-chain-specific IgG or mouse anti-rabbit light-chain-specific IgG (Jackson ImmunoResearch Laboratories) using enhanced chemiluminescence (ECL; GE Healthcare) or SuperSignal West Femto Chemiluminescent substrate (Pierce) detection reagents. The fold change in the ratio of phosphorylated protein to total protein was measured in ImageJ software by boxing each band per representative image with the rectangular selection tool, and calculating the total area of the band in pixels. The total area of the phosphorylated protein band in pixels was normalized to the total area of the total protein band in pixels. The average fold change is shown in figures. Immunoprecipitation. Cell lysate (500 mg) was incubated overnight with 5 ml of mouse anti-HA antibody (Covance) at 4 uC. The immunoprecipitates were collected with GammaBind G Sepharose beads (GE Healthcare) for 2 h at 4 uC. SDS-PAGE analysis and immunoblotting were performed as described above. Protein purification. Recombinant GST-ERK2, GST-MEK1, GST-ERK5 and GST-MEK5 proteins were expressed from pGEX-based vectors (see plasmids above) and purified as described previously 6 . Recombinant MEK1 WT , MEK1 DD (S218D/ S222D; DD), MEK1 CBM and MEK1 CBM/DD proteins were a gift from A. Stewart, E. Johnson and C. Cronin. Recombinant GST-MEK2 and GST-MEK5 were purchased from Abnova. Recombinant MBP was purchased from Millipore. In vitro kinase assays. MEK1, MEK2 and MEK5 in vitro kinase assays were performed as described previously 6 . In brief, 0.6 mg of recombinant GST-ERK2 K54R , GST-ERK5 K84R or MBP and 1.4 mg of recombinant MEK1, GST-MEK1, GST-MEK2 or GST-MEK5, or mutants thereof, were incubated for 30 min in 180 ml of kinase buffer in the presence or absence of 2.5 molar equivalents of CuSO 4 , AgNO 3 , FeNH 2 SO 4 , NiSO 4 or ZnSO 4 ( Fig. 1h and Extended Data Fig. 1a ), a seven-step titration of TTM (Sigma) from 0-50 mM (Fig. 1f) , a fixed 50 mM concentration of TTM (Figs 1j, n and 4g and Extended Data Fig. 1c ) and/or a fixed concentration of 2.5 mM CuSO 4 ( Fig. 1n and Extended Data Fig. 1c ) at 22 uC. Copper binding. Recombinant GST-MEK1, GST-MEK2, GST-MEK5 proteins or mutants thereof (1 mg) were incubated for 2 h in 500 ml of RIPA containing 30 ml of Cu-pentadentate resin (Affiland) or 30 ml of free pentadentate resin (Affiland) at 4 uC. SDS-PAGE analysis and immunoblot were performed as described above. Cu pulldown experiments were performed as described previously 6 . Metal-catalysed oxidation, mass spectrometry and data analysis. GST-MEK1 was loaded with Cu(II) by using a CuSO 4 -histidine complex as described previously 6 . Metal-catalysed oxidation (MCO) reactions were performed as described previously 26 . In brief, metal-catalysed oxidation (MCO) reactions were performed at 37 uC in 50 mM HEPES pH 8.0, 150 mM NaCl containing 40 mM GST-MEK1, 100 mM ascorbate and 1 mM H 2 O 2 . Untreated MEK1 was included as the control. The reactions were stopped by precipitating the proteins in methanol/chloroform followed by reduction for 30 min with 2.5 mM dithiothreitol (DTT) at 37 uC and alkylation with 20 mM iodoacetamide in the dark at room temperature for 30 min (refs 38, 39) . In-solution digestion was performed overnight at 37 uC with trypsin (1:40 enzyme:protein ratio; modified, sequencing grade; Promega), which hydrolyses peptide bonds at the carboxyl end of lysine and arginine, or chymotrypsin (1:60 enzyme:protein ratio; Sigma), which hydrolyses peptide bonds at the carboxyl end of aromatic or large hydrophobic side chains of tyrosine, tryptophan, phenylalanine, methionine and leucine. The digested peptide samples were desalted with stage tips 40 and freeze-dried with a SpeedVac. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses were performed on a Thermo Scientific LTQ Orbitrap XL mass spectrometer (Thermo Scientific) with a Finnigan Nanospray II electrospray ionization source. Digested peptides were injected onto a 75 mm 3 150 mm BEH C 18 column (particle size 1.7 mm; Waters) and separated using a Waters nanoACQUITY Ultra Performance LC (UPLC) System (Waters). The LTQ Orbitrap XL was operated in data-dependent mode using the TOP10 strategy as described previously 41 . In brief, each scan cycle was initiated with a full MS scan of high mass accuracy (375-1,800 m/z; acquired in the Orbitrap XL at 6 3 10 4 resolution setting and automatic gain control target of 10 6 ), which was LETTER RESEARCH followed by MS/MS scans (automatic gain control target 5,000; threshold 3,000) in the linear ion trap on the ten most abundant precursor ions. Selected ions were dynamically excluded for 30 s. Singly charged ions were excluded from MS/MS analysis. MS/MS spectra were searched by using the SEQUEST algorithm against the human MEK1 sequence. Search parameters allowed for two missed tryptic cleavages, a mass tolerance of 680 p.p.m., a static modification of 57.02146 Da (carboxyamidomethylation) on cysteine, and dynamic modifications of 15.99491 Da (oxidation) on methionine or histidine. The MS/MS spectra of matched peptides were validated manually. Modelling of the distance between the thiol groups of methionines or imidazole groups of histidines was performed with the threedimensional structure of MEK1 in complex with magnesium and ATP-cS determined at 2.1 Å (PDB 3EQD) 13 . Circular dichroism spectroscopy. Circular dichroism (CD) data were collected on a JASCO J-815 CD spectrometer with a JASCO Peltier device and water bath to control the temperature. Experiments were performed in a 1-mm cuvette at a protein concentration of 5 mM in 20 mM Tris-HCl pH 8.0 and 100 mM NaCl. Far-ultraviolet scans were collected from 200 nm to 250 nm. Thermal denaturation of MEK1 and MEK1 CBM proteins was monitored at 222 nm to estimate the protein melting temperature. The temperature ramp rate was 1 uC min 21 and data points were collected every 1 uC. All data are reported in units of mean residue ellipticity, which was calculated from [h] MRE 5 (h raw 3 MRW)/10cl, where h raw is the ellipticity in degrees, MRW is molecular mass in daltons divided by (number of residues 2 1), c is the protein concentration (g ml 21 ) , and l is the path length of the cuvette (cm), as described previously 27 . Differential scanning fluorimetry. Differential scanning fluorimetry data were collected on a CFX384 Touch TM Real-Time PCR Dectection System (Bio-Rad) at a protein concentration of 1.3 mM in 25 mM Tris-HCl pH 7.5, 20 mM MgCl 2 , 2 mM DTT using SYPRO orange as described previously 28 . The melting temperature was calculated by determining the maximum of the first-derivative curve of normalized data in Prism 5 (GraphPad) as described previously 28 . Mouse xenografts, drug treatments and diet alteration. MEFs (5 3 10 6 ) or melanoma cells (10 7 ) resuspended in PBS were injected subcutaneously into flanks of 8-12-week-old female SCID/beige mice (Charles River Laboratory) as described previously 42 . Unblinded drug treatments were as follows: vehicle (1% methylcellulose (Sigma), 1% dimethylsulphoxide (DMSO; Sigma)), 2.0 mg tetrathiomolybdate (TTM; Sigma) in vehicle, or 20 mg kg 21 vemurafenib (Chemietek) in vehicle every other day by oral gavage. Mice were fed with a normal diet (PMI 5053 Picolab Mouse Diet 20; LabDiet) or, where indicated, a Cu-deficient diet (CuD diet, TD.80388; Harlan Teklad). Mice fed with a CuD diet were administered deionized H 2 O (diH 2 O) supplemented with 20 mg l 21 CuSO 4 , diH 2 O alone, or diH 2 O supplemented with 3 g l 21 trientine dihydrocholoride (Sigma). All studies were approved by the Duke University Institutional Animal Care and Use Committee. Statistical analysis of tumour volumes at endpoint was performed with a one-tailed, unpaired t-test, with a 95% confidence interval for two group data sets or one-way analysis of variance (ANOVA) with a 95%, 99% or 99.9% confidence interval and Tukey's multiple comparison post test for three or more data sets in Prism 5 (GraphPad). Statistical analysis of the percentage of mice with tumours of at least 1.0 cm 3 versus time was analysed by using a survival curve log-rank (Mantel-Cox) test in Prism 5 (GraphPad). Mouse lung cancer model. Ctr1 flox/flox mice 22 were interbred with Braf CA/1 ;Trp53 flox/flox (BP) mice 23 , a gift from D. G. Kirsch, for three generations to generate Braf CA/1 ; Trp53 flox/flox ;Ctr1 1/1 and Braf CA/1 ;Trp53 flox/flox ;Ctr1 flox/flox mice. PCR was performed to detect wild-type, conditional and recombined alleles of Braf, Ctr1 and Trp53, as described previously 22, 23 . Cohorts of these animals of known genotype were administered 6 3 10 6 plaque-forming units of adenoviral Cre (University of Iowa) intranasally between 69 and 85 days of age. Mice were then monitored and killed euthanized three months later or at moribundity endpoints. All studies were approved by the Duke University Institutional Animal Care and Use Committee. Statistical analysis of percentage survival versus time was conducted with a survival curve log-rank (Mantel-Cox) test in Prism 5 (GraphPad). Analysis of lung tumours. To quantify the number of visible surface tumours per mouse, lungs were resected from five Ctr1 1/1 and five Ctr1 flox/flox BP mice of known genotype three months after treatment with AdCre and the numbers of tumours visible on the surface of lungs were counted. Statistical analysis of the average number of tumours per mouse was performed using a one-tailed, unpaired t-test, with a 95% confidence interval for two group data sets. To quantify the percentage of abnormal lung tissue, lungs were resected from five Ctr1 1/1 and five Ctr1 flox/flox BP mice three months after treatment with AdCre, fixed in 10% formalin and embedded in paraffin. Sections were deparaffinized, rehydrated and subjected to epitope retrieval before staining with haematoxylin (Surgipath) and eosin (Fisher Scientific). Photographs were taken at low power on an Olympus Vanox S microscope to encompass the entire lung; images were blinded, and the abnormal areas of adenoma and adenocarcinoma from each micrograph were circumscribed using Adobe Photoshop and the abnormal area in pixels was expressed as a percentage of the total lung area from all micrographs. Statistical analysis of the average percentage of abnormal tissue per mouse was performed with a one-tailed, unpaired t-test, with a 95% confidence interval for two group data sets. Immunohistochemistry. Three xenograft tumours from mice injected with BRAF V600Etransformed Ctr1 1/1 MEFs or lungs resected at moribundity endpoint from Ctr1 1/1 and Ctr1 flox/flox BP mice treated with AdCre were fixed in 10% formalin and embedded in paraffin. Sections were deparaffinized, rehydrated and subjected to epitope retrieval and stained with an anti-P-ERK1/2 (Thr 202/Tyr 204) antibody (Cell Signaling), followed by peroxidase-based detection with Vectastain Elite ABC Kits (Vector Labs) and counterstaining with haematoxylin. Photographs were taken of high-power fields of highest positivity (P-ERK IHC) on an Olympus Vanox S microscope. Images were blinded and tumours were circumscribed in P-ERK1/2-stained tissue images with the freehand selection tool in Image J, and the total area of the tumour in pixels was recorded. Tumour images were copied and pasted to new, blank images and colour thresholding was applied to determine positive-staining areas, using the same parameters for each tumour image. Areas staining positive by these parameters were selected and the positivestaining area in pixels was recorded. The percentage positive-staining area was calculated by dividing the positive-staining area of the tumour in pixels by the total area of the tumour in pixels. Statistical significance was determined with unpaired, one-tailed t-tests between treated and untreated, or between Ctr1 1/1 and Ctr1 flox/flox cohorts, using Prism 5 (GraphPad). Cell growth and soft agar assays. For growth-curve experiments, cells were plated at a density of 5,000 cells per well in six replicate wells in four 24-well plates. At days 0, 1, 2 and 3, one plate was fixed for 5 min in formalin, washed with PBS and stained for 30 min with 0.1% crystal violet (Sigma) and left to dry for at least 24 h. Stain was extracted in 200 ml of 10% acetic acid in each well, transferred to a 96-well plate, and the absorbance at 600 nm was measured with a GloMax Multi Detection System plate reader (Promega) in an unblinded fashion. Relative growth was determined by normalization to the signal at day 0 and plotted in Prism 5 (GraphPad). Anchorage-independent growth was assayed in six-well plates with 1 ml of 0.6% bactoagar media solution (final concentration 1 3 DMEM, 10% FBS, 1 3 penicillin/ streptomycin) as a bottom support layer; 5 3 10 4 cells per well were resuspended in DMEM (10% FBS, 1 3 penicillin/streptomycin) and mixed 1:1 with 0.6% bactoagar media solution with an appropriate concentration of DMSO or TTM to give a final bactoagar concentration of 0.3%, 100 nM TTM, 400 nM TTM, or an equivalent amount of DMSO and plated in triplicate. Each well was fed on days 3, 7, 14 and 21 with 300 ml of DMEM with the appropriate concentration of DMSO or TTM. Colonies were counted unblinded between days 21 and 28. Statistical analysis of soft agar growth was performed with a two-way ANOVA with a 99.9% confidence interval and Tukey's multiple comparison post test in Prism 5 (GraphPad).
